First Cancer Patients Treated in Latin America Using Advanced Radiotherapy Technology

Four patients with head and neck, rectal, and recurring prostate cancer are first in Latin America to benefit from new technology for fast delivery of image-guided intensity-modulated radiotherapy (IMRT), which potentially enables doctors to improve outcomes while extending modern care to more patients.

Physicians from Hope International Centro de Radioterapia of Guatemala (Guatemala City) are now treating four patients using RapidArc radiotherapy technology developed by Varian Medical Systems, Inc. (Palo Alto, CA, USA), one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

Clinicians at the center, which treats patients from across Central America, performed the first treatment for a 66-year-old attorney whose prostate cancer recurred a year after it was first treated using robotic surgery. His first RapidArc treatment was delivered in 3.16 minutes using two arcs, or rotations, of the machine around the patient. By comparison, conventional IMRT treatments would have taken eight to ten minutes.

Using the image-guidance technology that is integral to the RapidArc treatment process, clinicians were able to detect a 2 mm - 3 mm displacement of the targeted tumor after they positioned the patient for his first treatment. "We could then make a very fine adjustment in the patient's position, to ensure that we were accurately targeting the tumor and sparing surrounding tissues to the greatest extent possible,” said Luis A. Linares, M.D., medical director.

Dr. Linares and his medical team generated traditional IMRT treatment plans as well as RapidArc plans for all four patients, in order to compare and choose the one most likely to result in the best possible outcome. "In every case, the RapidArc plans were superior, as far as quality of the dose distribution was concerned,” Dr. Linares said. "We saw better coverage of the targeted tumor, and better normal tissue-sparing. For the rectal cancer patient, doses to the bladder and femoral heads were significantly lower with the RapidArc plan. For the prostate cancer patient, RapidArc did a better job of protecting both the bladder and the rectum. And for the patient with recurrent glioblastoma, we saw a definite advantage to the RapidArc plan, in terms of protecting the optic nerve and optic chiasm.”

RapidArc delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient and makes it possible to deliver advanced image-guided IMRT up to eight times faster than is possible with conventional IMRT. RapidArc technology directs the treatment beam at a tumor while continuously rotating around the patient. Traditional IMRT treatments are slower because they target tumors using a complex sequence of fixed beams from multiple angles. "Faster treatments have the potential to be even more precise, since there is less chance of the patient or tumor moving during treatment,” Dr. Linares said.

"We are pleased to hear that the first RapidArc treatments have now been delivered at this important cancer treatment facility in Central America,” said James Miles, Varian's director of operations for Latin American and the Caribbean. "RapidArc is enabling more and more cancer centers around the world to offer patients the most modern treatments available.”

Previous studies have demonstrated improved outcomes for prostate and head and neck cancer patients treated with IMRT as compared with other forms of radiotherapy, and revealed the magnitude of tumor motion that can take place during a prostate cancer treatment.

Related Links:
Hope International Centro de Radioterapia of Guatemala
Varian Medical Systems